TheracosBio瀟ã¯ãç±³åœé£åå»è¬åå±ïŒFDAïŒãBrenzavvyïŒbexagliflozinïŒãæ¿èªããããšãçºè¡šããŸããã Brenzavvyã¯ãå¡©ç³éæ¬äœ2ïŒSGLT2ïŒé»å®³è¬ã§ãé£äºãéåã«å ããŠã2åç³å°¿ç ã®æ£è ã®è¡ç³ã³ã³ãããŒã«ãæ¹åããããã®è¿œå æ²»çè¬ãšããŠäœ¿çšãããŸãã Brenzavvyã¯1åç³å°¿ç ãç³å°¿ç æ§ã±ãã¢ã·ããŒã·ã¹ã®æ²»çã«ã¯é©ããŠããŸããã Brenzavvyã¯ãbexagliflozinãŸãã¯ä»»æã®ã¿ãã¬ããæåã«å¯ŸããŠéæçã®æ£è ã«ã¯äœ¿çšçŠæ¢ã§ããã2åç³å°¿ç ã®æ£è ã®æ«æè èçŸæ£ãéæãåããŠããæ£è ã®æ²»çã«ã¯äœ¿çšãããŠããŸããã FDAã®æ¿èªã¯ã5000人以äžã®2åç³å°¿ç æ£è ã察象ãšãã23ã®èšåºè©Šéšã®çµæã«åºã¥ããŠããŸãã Phase 3ã®ç 究ã§ã¯Brenzavvyããåç¬çæ³ãã¡ã¿ãã©ãŒãã³ãŸãã¯æšæºçãªæ²»çãšã®äœµçšïŒã¡ã¿ãã©ãŒãã³ãã¹ã«ããã«ãã€ã³ã¹ãªã³ãDPP4é»å®³è¬ãªã©ïŒã§24é±åŸã«ããã¢ã°ããã³A1cãšç©ºè ¹æè¡ç³ãææã«äœäžãããŸããã Brenzavvyã¯äœéæžå°ãéå§äœçšãç®çãšããæäžãèªããããŠããŸããããèšåºè©Šéšã§ã¯äž¡äœçšãææã«çããããšã確èªãããŸããã
Brenzavvyæ²»çã¯ã尿现管濟éçïŒeGFRïŒã30mL / min / 1.73m2以äžã®æ人ã察象ãšããŸããeGFRã60æªæºã§30mL / min / 1.73m2以äžã®æ£è ã¯ç¬¬3段éã®æ ¢æ§è èç ã§ããããããã®æ£è ã«ã¯ä¹³é žã¢ã·ããŒã·ã¹ã®ãªã¹ã¯ããããããã¡ããã©ã«ãã³ã¯äœ¿çšãããªãããšãå€ãã§ãã
ä»æ¥ã®FDAã®æ¿èªã¯ãTheracosBio瀟ã«ãšã£ãŠéèŠãªãã€ã«ã¹ããŒã³ã§ããã2åç³å°¿ç ãæ£ãæ£è ã«éèŠãªæ²»çãªãã·ã§ã³ãæäŸããããšã«ãªããŸããBrenzavvyã®äžåžã楜ãã¿ã§ãã